Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Phase 1/2 Study of Venetoclax/Daratumumab/Dexamethasone for Previously Treated Systemic Light-Chain Amyloidosis With Translocation (11;14)

NCT05486481 is registered in ClinicalTrials.gov with Alfred Chung, MD as lead sponsor.

NCT NCT05486481
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05486481 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Phase 1/2 Study of Venetoclax/Daratumumab/Dexamethasone for Previously Treated Systemic Light-Chain Amyloidosis With Translocation (11;14)
Lead sponsor
Alfred Chung, MD
Phase
Phase 1/2
Overall status
Withdrawn
Start date
January 8, 2024
Completion date
December 31, 2028
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

al amyloidosis, light chain (al) amyloidosis, systemic light chain disease